Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ: CPRX )

21.92 -0.88 (-3.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,510,325
Open 22.85
Bid (Size) 21.50 (85)
Ask (Size) 21.98 (10)
Prev. Close 22.80
Today's Range 21.34 - 22.98
52wk Range 13.12 - 24.27
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
One of Catalyst's key products has protection against a knockoff from Teva until 2035. 
Via Investor's Business Daily

Performance

YTD
+1.86%
+1.86%
1 Month
+2.72%
+2.72%
3 Month
+6.20%
+6.20%
6 Month
+30.87%
+30.87%
1 Year
+51.28%
+51.28%

More News

Read More
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
NASDAQ:CPRX, a growth stock which is not overvalued.
Via Chartmill
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Via Chartmill
Should you consider NASDAQ:CPRX for growth investing?
Via Chartmill
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Via Chartmill
Arcellx Stock Earns 82 Relative Strength Rating
Via Investor's Business Daily
Neurocrine Biosciences Stock Sees RS Rating Upgrade
Via Investor's Business Daily
For those who appreciate value investing, NASDAQ:CPRX is a compelling option with its solid fundamentals.
Via Chartmill
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Unlocking the Growth Potential of NASDAQ:CPRX.
Via Chartmill
Why NASDAQ:CPRX qualifies as a high growth stock.
Via Chartmill
Is NASDAQ:CPRX on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
Via Investor's Business Daily
Don't overlook NASDAQ:CPRX—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Despite its impressive fundamentals, NASDAQ:CPRX remains undervalued.
Via Chartmill
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
NASDAQ:CPRX is showing good growth, while it is not too expensive.
Via Chartmill
NASDAQ:CPRX is an undervalued gem with solid fundamentals.
Via Chartmill
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
BioNTech Stock Got A IBD RS Rating Lift
Via Investor's Business Daily
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Vericel Stock Sees RS Rating Shoot Higher
Via Investor's Business Daily
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.